Every material Form 8-K Tenaya Therapeutics, Inc. has filed with the SEC since July 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Tenaya Therapeutics reported a third-quarter 2026 net loss of $18.9 million, or $0.08 per share, down from $20.3 million, or $0.12 per share, a year earlier. The company said its cash covers planned operations into the fourth quarter of 2027, but cash has fallen from $100.5 million at December 31, 2025, and the nine-month net loss widened to $81.6 million from $70.4 million.
Q3 2026 collaboration revenue was $1.7 million, compared with none in Q3 2025.
Q3 2026 included a $666,000 impairment loss; nine-month impairment losses totaled $22.5 million.
Cash and cash equivalents were $66.8 million at September 30, 2026, versus $100.5 million at December 31, 2025.
FDA granted RMAT designation to TN-401 in September 2026; further TN-201 and TN-401 updates are planned by year end.
Tenaya Therapeutics reported a second-quarter 2026 net loss of $43.4 million, or $0.20 per share, compared with $23.3 million, or $0.14 per share, a year earlier. The company said the increase was mainly due to a $21.8 million non-cash impairment charge tied to the early termination of its Union City manufacturing facility lease. Cash and cash equivalents fell to $78.1 million at June 30, 2026, from $100.5 million at December 31, 2025, and the company said cash should fund operations through Q3 2027, including a $10.0 million upfront payment from Alnylam.
Net loss of $43.4 million, or $0.20 per share, for the quarter ended June 30, 2026, versus $23.3 million, or $0.14 per share, in the same quarter of 2025
$21.8 million non-cash impairment charge related to the early termination of the Union City GMMC facility lease
Collaboration revenue of $1.1 million in the quarter, compared with none in the prior-year quarter
Cash and cash equivalents of $78.1 million at June 30, 2026, which the company expects to fund planned operations through Q3 2027
Tenaya Therapeutics agreed on June 29, 2026 to terminate its lease for a roughly 94,046 square foot manufacturing facility in Union City, California, which it had already decommissioned in 2025 to reduce costs. The company will forfeit a $1,750,000 security deposit and pay a one-time termination fee of about $294,200, and it plans to move AAV manufacturing to a contract manufacturer.
Lease termination agreement with Terreno Park Union City LLC dated June 29, 2026
Lease was originally set to expire in July 2031; termination takes effect August 31, 2026
Company forfeits $1,750,000 security deposit and pays a one-time fee of about $294,200
Company plans to transfer AAV manufacturing to a contract development manufacturing organization
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Tenaya Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →